Aurobindo Pharma to Launch Generic of Novartis Drug After US FDA Nod

's subsidiary Eugia Pharma Specialities has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Everolimus tablets, a generic version of Novartis’ Zortress medication used in transplant and oncology treatments. The product is bioequivalent to the branded drug and opens access to an estimated $78 million US market. The company plans to begin commercialisation in the near term, adding to its expanding portfolio of generic offerings in the regulated US market. This approval adds to Aurobindo’s track record of obtaining complex generics approvals from the US regulator. What This Means * USFDA approval for Everolimus provides Aurobindo with entry into a new mid-sized US generics market. * Adding regulated market products can help diversify revenue streams beyond domestic markets. * Approval reinforces the company’s compliance and manufacturing credentials in stringent regulatory environments. Key Things to Watch Going Forward 1. Launch timing and initial sales uptake in the US. 2. Pricing competitiveness against other generic manufacturers. 3. Market share in transplant and oncology segments. 4. Further USFDA approvals in complex or high-value categories. Opinion The USFDA nod for a generic version of a Novartis drug from Aurobindo Pharma’s arm signals steady execution in its global generics strategy. With many blockbuster drugs losing exclusivity, Indian pharma players are increasingly targeting these opportunities to drive sales in higher-margin regulated markets. Everolimus’ approval not only adds a new product to Aurobindo’s US portfolio but also demonstrates its capability to meet stringent regulatory standards. While competition in the generics space remains intense, early entry and effective pricing could translate into a meaningful revenue stream, especially as the company continues to broaden its footprint in key therapeutic areas. Source: The Hindu No Recommendations